Scholarlink

Background <p>Carbapenemase-producing <i>Enterobacterales</i> (CPE) are associated with substantial morbidity and mortality with limited treatment options and have an ability to spread rapidly in healthcare settings. We analyzed surveillance data from the Canadian Nosocomial Infection Surveillance Program to describe trends and the epidemiology of CPE from 2010 to 2023.</p> Methods <p>Participating acute-care hospitals submitted eligible isolates to the National Microbiology Laboratory for detection of carbapenemase genes. Trained infection control professionals applied standardized definitions to collect epidemiological data by chart review from 30–97 hospitals from 2010 to 2023.</p> Results <p>The national incidence of CPE infection (0.03 to 0.14 per 10,000 patient days; R<sup>2</sup> = 0.76) and colonization (0.02 to 0.78 per 10,000 patient days; R<sup>2</sup> = 0.83) increased exponentially from 2010 to 2023. We identified rapidly rising rates of healthcare-associated (HA) CPE infections from 2019 to 2023 (0.05 to 0.09 per 10,000 patient-days, <i>p</i> = 0.04), attributed to select hospitals (7/97) which accounted for half (53%) of all HA-CPE infections in 2023. Similarly, we identified that 2023 HA-CPE colonization rates were highest in medium (201–499 beds) and large (≥500 beds) hospitals in the Central region.</p> <p>Most patients did not report international travel (66%) nor receipt of medical care abroad (74%). Travel and receipt of medical care were less commonly reported among <i>bla</i><sub>KPC</sub> associated cases (7.1% and 5.3% respectively) compared to <i>bla</i><sub>NDM</sub> (55% and 45% respectively) and <i>bla</i><sub>OXA-48</sub> (57% and 39%) associated cases. Furthermore, <i>bla</i><sub>KPC</sub> was the predominant carbapenemase among all HA-CPE isolates (62%, 950/1,534).</p> Conclusions <p>Surveillance data from a national network of Canadian acute care hospitals indicates that while the incidence of CPE in Canada remains low, it is accelerating at an exponential rate. Our findings suggest that nosocomial transmission is driving the recent increase in CPE incidence in Canada. Improved infection control measures and antimicrobial stewardship as well as access to newer antimicrobials are all urgently needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The evolving epidemiology of Carbapenemase-producing Enterobacterales in Canadian acute care facilities, 2010–2023

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月12日

查看全文
  • Robyn Mitchell,
  • Laura Mataseje,
  • Joëlle Cayen,
  • Erin McGill,
  • Kristine Cannon,
  • Ian Davis,
  • Tamara Duncombe,
  • Chelsey Ellis,
  • Jennifer Ellison,
  • Jennifer Happe,
  • Susy S. Hota,
  • Kevin C. Katz,
  • Pamela Kibsey,
  • Santina Lee,
  • Jerome A. Leis,
  • Xena Li,
  • Allison McGeer,
  • Jessica Minion,
  • Sonja Musto,
  • Connie Patterson,
  • Ewa Rajda,
  • Stephanie W. Smith,
  • Jocelyn A. Srigley,
  • Kathryn N. Suh,
  • Nisha Thampi,
  • Jen Tomlinson,
  • Joseph Vayalumkal,
  • Kristen Versluys,
  • Titus Wong,
  • Yves Longtin

摘要

Background

Carbapenemase-producing Enterobacterales (CPE) are associated with substantial morbidity and mortality with limited treatment options and have an ability to spread rapidly in healthcare settings. We analyzed surveillance data from the Canadian Nosocomial Infection Surveillance Program to describe trends and the epidemiology of CPE from 2010 to 2023.

Methods

Participating acute-care hospitals submitted eligible isolates to the National Microbiology Laboratory for detection of carbapenemase genes. Trained infection control professionals applied standardized definitions to collect epidemiological data by chart review from 30–97 hospitals from 2010 to 2023.

Results

The national incidence of CPE infection (0.03 to 0.14 per 10,000 patient days; R2 = 0.76) and colonization (0.02 to 0.78 per 10,000 patient days; R2 = 0.83) increased exponentially from 2010 to 2023. We identified rapidly rising rates of healthcare-associated (HA) CPE infections from 2019 to 2023 (0.05 to 0.09 per 10,000 patient-days, p = 0.04), attributed to select hospitals (7/97) which accounted for half (53%) of all HA-CPE infections in 2023. Similarly, we identified that 2023 HA-CPE colonization rates were highest in medium (201–499 beds) and large (≥500 beds) hospitals in the Central region.

Most patients did not report international travel (66%) nor receipt of medical care abroad (74%). Travel and receipt of medical care were less commonly reported among blaKPC associated cases (7.1% and 5.3% respectively) compared to blaNDM (55% and 45% respectively) and blaOXA-48 (57% and 39%) associated cases. Furthermore, blaKPC was the predominant carbapenemase among all HA-CPE isolates (62%, 950/1,534).

Conclusions

Surveillance data from a national network of Canadian acute care hospitals indicates that while the incidence of CPE in Canada remains low, it is accelerating at an exponential rate. Our findings suggest that nosocomial transmission is driving the recent increase in CPE incidence in Canada. Improved infection control measures and antimicrobial stewardship as well as access to newer antimicrobials are all urgently needed.